Recursion Pharmaceuticals (RXRX) Operating Expenses (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Operating Expenses came in at $135.0 million in Q1 2026, down 34.51% YoY from $206.1 million in Q1 2025, and down 6.18% on a QoQ basis from $143.9 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Operating Expenses (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Operating Expenses data on file, last reported at $135.0 million in Q1 2026.
- Quarterly Operating Expenses fell 34.51% year-over-year to $135.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651.7 million (up 2.82% YoY) and the FY2025 annual result came in at $722.8 million, up 34.39% from the prior year.
- Operating Expenses fell to $135.0 million in Q1 2026, from $143.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $206.1 million in Q1 2025 to a low of $61.3 million in Q1 2022.
- A 5-year average of $122.1 million and a median of $110.1 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2025 — Operating Expenses jumped 87.15% — and 2026, when it tumbled 34.51%.
- Tracing RXRX's Operating Expenses over 5 years: stood at $74.7 million in 2022, then jumped by 47.1% to $109.8 million in 2023, then jumped by 71.47% to $188.3 million in 2024, then dropped by 23.6% to $143.9 million in 2025, then retreated by 6.18% to $135.0 million in 2026.
- The last three Operating Expenses figures came in at $135.0 million (Q1 2026), $143.9 million (Q4 2025), and $177.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 142.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142.64 Mn |
| Mar 31, 2026 | 134.98 Mn |
| Dec 31, 2025 | 143.87 Mn |
| Sep 30, 2025 | 177.38 Mn |
| Jun 30, 2025 | 195.45 Mn |
| Mar 31, 2025 | 206.11 Mn |
| Dec 31, 2024 | 188.31 Mn |
| Sep 30, 2024 | 124.44 Mn |
| Jun 30, 2024 | 114.96 Mn |
| Mar 31, 2024 | 110.13 Mn |
| Dec 31, 2023 | 109.82 Mn |
| Sep 30, 2023 | 110.08 Mn |
| Jun 30, 2023 | 92.73 Mn |
| Mar 31, 2023 | 82.00 Mn |
| Dec 31, 2022 | 74.66 Mn |
| Sep 30, 2022 | 75.73 Mn |
| Jun 30, 2022 | 73.87 Mn |
| Mar 31, 2022 | 61.31 Mn |
| Dec 31, 2021 | 67.49 Mn |
| Sep 30, 2021 | 48.94 Mn |